In the related ROP treatment studies, the RAINBOW study has proved the efficacies and safeties of intravitreal razumab, which makes intravitreal injection of anti-VEGF drug razumab gradually become an important means. The gene discussed is VEGFA; the disease is retinopathy of prematurity.